Story

The Full Story

Lee & Man Chemical is a cyclical chlor-alkali producer that management has tried — in every annual report since the 2007 Hong Kong listing — to describe as something more than a commodity business. The narrative has moved in distinct phases: the early captive-supplier phase of 2007-2014 when chemical output was partly absorbed by sister paper company Lee & Man Paper (2314.HK); the 2015-2018 margin boom when Chinese environmental tightening shut out smaller chlor-alkali capacity and lifted caustic-soda and chloromethane prices; the 2020-2021 COVID-era second peak when EPS of HK$1.56 was the highest in company history; and the 2022-2024 collapse as commodity prices reverted and the promised lithium-battery-additive pivot arrived into an oversupplied market. Through all four phases the same two executives — Chairman Ms. Wai Siu Kee and CEO Mr. Lee Man Yan — have signed the chairman's statement, so the narrative drift is not about new leadership telling a new story; it is about the same leaders quietly editing the prior year's promises.

1. The Narrative Arc

The chart is the story. Revenue traced a long commodity staircase from HK$1.6B in FY2014 to a HK$5.87B peak in FY2022, but the shape of net income tells the truer tale: two boom episodes (FY2017-2018 and FY2020-2022) separated by a soft patch in FY2019-2020, and a hard commodity reset through FY2023. Net margin peaked at 24.8% in FY2021 when one-ton caustic soda pricing exceeded RMB 5,000 during the Guangxi and Inner Mongolia power rationing, and collapsed to 9.9% in FY2023 when caustic reverted to RMB 950 per ton — a 26% YoY decline the chairman's statement attributed to "weak market sentiment in the manufacturing sector" without acknowledging the prior year's promises implicitly assumed that pricing would hold.

Three inflection points worth naming

The first is the 2017 chlor-alkali margin regime shift, visible as a step-change from 11.9% net margin in FY2016 to 23.6% in FY2017. Management explained this at the time as "benefits from the national environmental protection campaign." It was real — Chinese environmental enforcement forced smaller chlor-alkali producers to close — but the language carried a claim of durability it never earned.

The second is the COVID peak of FY2021: caustic soda spot prices spiked in late 2021 as power rationing in Guangxi and Inner Mongolia took chlor-alkali capacity offline. H2 2021 alone delivered HK$701M of net income — more than all of FY2018. By early 2022 the chairman's statement was describing the business as positioned for "high-value-added chemical products" and "vertical integration of the production chain."

The third is the FY2023 reversal. Revenue fell 31.0% to HK$4,051M and profit fell 65.3% to HK$401M. Caustic soda pricing dropped 26% YoY to RMB 950/ton, methyl chloride dropped 50% to RMB 2,550/ton, chloroform dropped 41%. The lithium-battery-additive story, which had been the centerpiece of the post-2018 capex narrative, suffered what the FY2023 chairman's statement called "serious fluctuation in the prices of lithium-ion battery raw materials" causing downstream customers to cut purchases. The FY2023 filing is the first one in a decade to describe the forward outlook as simply "a year testing to the operational resilience of enterprises" — language that is effectively a confession that the prior specialty/new-energy narrative had not arrived on schedule.

2. What Management Emphasized — and Then Stopped Emphasizing

The heatmap shows a clean pattern. Hydrogen fuel-cell commercial sales was a launch story in FY2019 — the annual report explicitly noted that "sales of commercial hydrogen have begun in the fourth quarter of 2019, contributing to the development of hydrogen-cell batteries" — and was never mentioned again at material weight after FY2021. It simply fell out of the narrative without explanation.

Lithium battery electrolyte additives followed a textbook hype cycle. The FY2018 chairman's statement announced the Zhuhai Gaolan Port plant "is expected to commence its production by the end of 2019"; FY2019 slipped this to "mid-2020"; FY2023 was the first year the segment was discussed as a disappointment, and by FY2024 the MD&A does not break out lithium-additive revenue at all. In parallel, the FY2023 filing made the quiet but important disclosure that "the Group is also preparing to adjust the purpose of the new land acquired in Jiangxi and use it to develop high-end fluoropolymers" — translation: the lithium land in Jiangxi is being repurposed because the original demand thesis broke.

Automated Production Control and cost control now dominate — together they are the core of the 2023-2024 narrative. These are the topics that always get louder when the cyclical topics get quieter. The FY2024 MD&A proudly notes "a slight increase in gross profit" from "results of cost control and implementation of intelligent transformation management" — which is simply management describing the thing they can control when the thing that actually drives profit (caustic soda price) is moving against them.

RIVERDALE is the small property development in Jiangsu that sells residential units. Its appearance in the 2023-2024 narrative at higher intensity is notable not because it matters — property revenue was HK$29M in FY2024 out of HK$3.95B group total — but because management is filling narrative space left by the collapsed lithium story.

3. Risk Evolution

Three shifts are meaningful. First, the 2018-2019 framing of "increasingly strengthening of the safety and environmental protection requirements of the Chinese government" was treated as both a risk (compliance costs) and a tailwind (capacity rationalisation). That dual framing disappears after 2021 — environmental tightening no longer closes competitor capacity at material scale because the pool of marginal small producers has already shrunk.

Second, weak downstream manufacturing demand goes from a minor footnote in the FY2019 Sino-US trade discussion to the dominant concern in FY2023-2024. The FY2024 MD&A introduces a new phrase — the manufacturing industry faced intense "involution" competition — that is arguably the most honest thing Chinese industrial management has said about the post-2022 domestic environment. Note the word choice: "involution" (内卷) is domestic-oligopoly-driving-prices-down language, not a cyclical demand softness claim.

Third, lithium raw material price volatility arrives as a top-level risk for the first time in FY2023 and is already downgraded in FY2024, consistent with the segment's deprioritization. A risk only gets top billing once; when it is downgraded without clear resolution, the underlying business has usually been quietly scaled back.

4. How They Handled Bad News

Two episodes are instructive.

The pattern is consistent — each year's forward-looking statement is compatible with the prior year's, but slightly narrower in scope. No single statement is retracted; the ambition shrinks one notch per year. This is how Chinese industrial management typically handles strategic walk-backs, and it is effective at avoiding accountability while also being visibly honest to a careful reader.

5. Guidance Track Record

Lee & Man Chemical provides minimal quantitative forward guidance. The chairman's statements contain capacity milestones, commissioning dates, and prospect language but almost never revenue or EPS targets. That makes the track record table below necessarily qualitative.

Credibility score: 6 / 10

The six reflects a real split. On the things management fully controls — safety certification, plant automation, capex execution, dividend discipline, balance-sheet conservatism (net-debt/equity only 6.0% at end-FY2024) — the track record is excellent and has never delivered a surprise to the downside. On the things the market cares about most — strategic direction, new-business economics, and the cyclical call — the record is considerably weaker. Lithium-battery additives were promised as a growth engine for five consecutive annual reports and have quietly been downgraded to one product line among several, with the underlying land asset repurposed. That is a pattern, not an incident.

6. What the Story Is Now

Lee & Man Chemical today describes itself accurately for the first time in several years: a commodity chlor-alkali, chloromethane, hydrogen peroxide and PTFE producer with roughly 590,000 tons of caustic-soda capacity and 400,000 tons of CMS capacity across Jiangsu, Jiangxi and Zhuhai plants, operating near full utilisation with tight cost control and a conservative balance sheet. The specialty / new-energy ambition has been scaled down to an optionality: VC and FEC lithium-additive lines commissioned in mid-2024, Jiangxi land now earmarked for fluoropolymers, and R&D spend holding at about 3.4% of revenue.

What has been de-risked. Balance-sheet leverage is negligible (net-debt/equity 6.0%, cash HK$291M, net debt HK$358M), and operating cash generation easily funds remaining capex. Capex commitments stepped down from HK$285M contracted at year-end FY2023 to HK$149M at year-end FY2024 — the company is no longer in a growth-capex cycle. The Lee family shareholder structure and board composition (Chairman Wai Siu Kee and CEO Lee Man Yan have both been in their roles the entire period under review) means there is no governance surprise risk in the near term.

What remains stretched. The FY2024 MD&A uses the word "involution" to describe the Chinese chemical market — management is effectively saying that even at current depressed pricing, domestic competitors will not rationalise voluntarily, and caustic soda at RMB 940/ton is the new equilibrium rather than a trough from which recovery is timed. The FY2025 interim data already shows gross margin recovering to 36.3% in H1 2025 before easing to 32.6% in H2 2025, so the worst-case pricing fear has been softened, but the higher-margin narrative from FY2017-2022 has structurally ended.

What the reader should believe versus discount. Believe the operational picture — plant utilisation, automation gains, dividend discipline, captive demand from related-party Lee & Man Paper (HKEX: 2314) for caustic soda and bleach. Believe the balance-sheet conservatism. Discount the forward-looking specialty/new-energy optionality until revenue contribution is disclosed in a segment table — every prior iteration of that story has been slowly retired without an explicit retraction. And read the phrase "Automated Production Control" each year as a reliable signal that management is emphasising what it can control because the cyclical drivers have moved against it.